Oncocyte (OCX) filed a registration statement Friday for the resale of up to around 10.6 million shares of its common stock by a selling shareholders from time to time.
About 7.5 million shares for resale were issued in a private placement, while around 3.1 million shares are issuable upon the exercise of pre-funded warrants.
The company said it will not receive any proceeds from the sale of the shares.
It will receive the applicable proceeds from the exercise of the pre-funded warrants, if they are exercised for cash, at an exercise price of $0.001 per share. Oncocyte said it intends to use those proceeds, if any, for general corporate purposes.
Price: 3.04, Change: -0.17, Percent Change: -5.30
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.